MK-4700 + Pembrolizumab for Cancer
Trial Summary
What is the purpose of this trial?
The goal of this study is to learn about the safety of different doses of MK-4700 and if people tolerate them. The study will also measure what happens in a person's body over time when MK-4700 is given alone or with pembrolizumab (MK-3475) in order to find a dose that is safe, tolerated, and may work to treat certain types of cancer.
Research Team
Medical Director
Principal Investigator
Merck Sharp & Dohme LLC
Eligibility Criteria
This trial is for adults with advanced or metastatic solid tumors who have tried, can't tolerate, or refused all other treatments. It's open to those with specific cancers like HNSCC, melanoma, NSCLC, cervical cancer, TNBC, UC, or RCC. Participants must have well-controlled HIV if infected and normal heart function.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive escalating doses of MK-4700 every three weeks for a maximum of 35 cycles (approximately 2 years). Eligible participants may cross over to receive MK-4700 and pembrolizumab combination therapy.
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- MK-4700
- Pembrolizumab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Merck Sharp & Dohme LLC
Lead Sponsor
Chirfi Guindo
Merck Sharp & Dohme LLC
Chief Marketing Officer since 2022
Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business
Robert M. Davis
Merck Sharp & Dohme LLC
Chief Executive Officer since 2021
JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University